Baseline parameter | HR (95% CI) | P value |
Treatment | ||
Abatacept+MTX vs MTX | 0.71 (0.46 to 1.09) | 0.1171 |
Abatacept vs MTX | 0.80 (0.51 to 1.25) | 0.3276 |
DAS28-CRP | 0.84 (0.64 to 1.11) | 0.2231 |
SJC (28 joints) | 1.02 (1.00 to 1.04) | 0.1060 |
PtGA (0–100 mm VAS) | 1.00 (0.99 to 1.01) | 0.9692 |
Baseline corticosteroid use (yes vs no) | 1.71 (1.11 to 2.63) | 0.0159 |
RA symptom duration (<3 vs ≥3 months) | 0.97 (0.66 to 1.42) | 0.8588 |
Smoking status (yes† vs no) | 0.91 (0.63 to 1.33) | 0.6376 |
Anti-CCP2 (positive vs negative) | 1.06 (0.73 to 1.54) | 0.7543 |
HRs and p values were based on a Cox proportional-hazards model including the following baseline parameters: randomised treatment, DAS28-CRP, SJC, PtGA, corticosteroid use, RA symptom duration, smoking status and anti-CCP2 antibody status. RA flare was defined as ≥2 of doubling of tender and swollen joint counts from month 12, increase in DAS28-CRP ≥1.2 from month 12 or investigator’s clinical judgement of RA.
*All randomised and treated patients who entered the withdrawal period (n=146).
†Includes previous and current smokers.
Anti-CCP2, anticyclic citrullinated peptide 2; DAS28-CRP, Disease Activity Score 28-C reactive protein ; MTX, methotrexate; PtGA, Patient Global Assessment of Disease Activity; RA, rheumatoid arthritis; SJC, swollen joint count; VAS, Visual Analogue Scale.